You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
REBIF is indicated for the treatment of:
? Patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. High risk can be inferred from cerebral MRI with 2 or more lesions suggestive of demyelination.,? Ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years.
REBIF therapy should not be initiated in secondary progressive MS patients who no longer experience relapses.¾
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
REBIF is indicated for the treatment of:
? Patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. High risk can be inferred from cerebral MRI with 2 or more lesions suggestive of demyelination.,? Ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years.
REBIF therapy should not be initiated in secondary progressive MS patients who no longer experience relapses.¾
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
REBIF is indicated for the treatment of:
? Patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. High risk can be inferred from cerebral MRI with 2 or more lesions suggestive of demyelination.,? Ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years.
REBIF therapy should not be initiated in secondary progressive MS patients who no longer experience relapses.¾
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
